Descartes-08

Descartes-08 (resecabtagene autoleucel, or rese-cel) is Cartesian Therapeutics' autologous CAR-T therapy that targets BCMA (B-cell maturation antigen), a protein on plasma cells. It is being developed for generalized myasthenia gravis (gMG), an autoimmune disease where the body's own antibodies attack the connection between nerves and muscles, causing progressive weakness. The Phase 2b placebo-controlled trial (NCT04146051) reported positive results published in Nature Medicine in early 2026 [1][2], and Cartesian has moved into a registrational Phase 3 (NCT06799247) that started recruiting in 2025 [3]. The key differentiator: this is an mRNA-based CAR-T, meaning the CAR construct is transient rather than permanently integrated into the T-cell genome. That design choice sidesteps the harsh lymphodepletion chemotherapy required for traditional CAR-T and gives the safety profile a chance to look tolerable enough for autoimmune patients who are not dying tomorrow. If Phase 3 confirms the Phase 2b signal, this becomes the first cell therapy approved for MG, and Cartesian, a small-cap biotech valued in the $500M range, becomes an acquisition target or a specialty commercial company overnight [4].

Novel compound, no approvals anywhere. Phase 2b (NCT04146051, n=30) is complete with data published in Nature Medicine in early 2026 [1]. The Phase 3 registrational trial (NCT06799247, n=100) is actively recruiting in generalized MG with MG-ADL (Myasthenia Gravis Activities of Daily Living, a patient-reported 8-item scale scoring functional impairment from talking to breathing) as the primary endpoint [3]. Cartesian is running Descartes-08 in parallel across other autoimmune indications: systemic lupus erythematosus (NCT06038474), autoantibody myositis (NCT07391605, Phase 2), and a pediatric autoimmune basket (NCT07089121). Descartes-08 holds FDA Orphan Drug Designation for generalized MG (gMG has an estimated US prevalence of roughly 65,000 to 80,000 patients, well under the 200,000-patient orphan threshold), which carries 7-year post-approval market exclusivity plus prescription-drug user fee waivers. No breakthrough or fast-track designation has been publicly disclosed for the MG program as of the FY2025 10-K filing [4]. That is slightly surprising given the placebo-controlled positive readout, and worth watching. Expected timing: Phase 3 primary completion likely late 2027 based on the ADL endpoint window and enrollment target of 100, with a Biologics License Application (BLA, the FDA submission required for biologic drug approval) targeted by Cartesian for 2027 per their FY2025 annual report [4]. Cartesian ended 2025 with $126.9M in cash plus a $150M term-loan facility from K2 HealthVentures ($50M initial tranche funded, additional tranches milestone-gated), extending runway to 2028 [4]. The milestone conditionality on the remaining term-loan tranches is a real, if secondary, financing risk investors should track.

Myasthenia gravis happens because B cells that have matured into plasma cells crank out antibodies against the acetylcholine receptor (AChR) at the neuromuscular junction. Those antibodies block the signal from nerve to muscle, and the muscle stops responding. The result is fatigable weakness, droopy eyelids, difficulty swallowing, and sometimes respiratory failure. The current standard of care attacks the antibodies themselves (efgartigimod, ravulizumab) or broadly suppresses the immune system (steroids, IVIG, rituximab). None of them eliminate the plasma cells that keep making the pathogenic antibodies in the first place. BCMA (B-cell maturation antigen, gene name TNFRSF17) is a receptor sitting on the surface of mature plasma cells. It is what those cells use to receive survival signals from BAFF and APRIL. A CAR-T engineered to recognize BCMA finds plasma cells and kills them, drying up the pathogenic antibody supply at the source. The mechanism is validated in multiple myeloma, where two anti-BCMA CAR-Ts (ide-cel, cilta-cel) are FDA-approved. Cartesian's twist is delivering the CAR as mRNA instead of viral DNA. The CAR expresses for days, not years, so the treatment is dosed as multiple infusions and skips the lymphodepletion chemo. Cartesian's platform also uses CD8+ cytotoxic T cells exclusively rather than the bulk CD4+/CD8+ T-cell populations used in standard CAR-T manufacturing. That design choice narrows the product to the killer-cell lineage and may contribute to the low cytokine release seen in trials, since CD4+ helper cells are a major source of the inflammatory cytokines that drive CRS. Preclinical work in myeloma established the platform [5], and the Phase 1b/2a MG-001 study showed both feasibility and an early clinical signal in MG [6].

NCT04146051 is a randomized, double-blind, placebo-controlled Phase 2b in generalized myasthenia gravis, n=30, with Cartesian as sponsor [7]. The primary endpoint is the proportion of patients with MG Composite improvement of at least 5 points. MG Composite is a clinician-scored 10-item scale that combines ocular, bulbar, respiratory, and limb weakness measures, weighted by clinical importance, into a single score, and it is one of the FDA-accepted efficacy scales for MG trials. Six infusions given weekly, no lymphodepletion, follow-up out to 12 months. The Nature Medicine paper reported statistically significant MG-ADL and quantitative MG improvements at month 4 versus placebo, with the effect deepening over time and durability out to at least a year in an open-label extension [1][2][8]. That is a well-designed trial for a Phase 2b: placebo control in a rare disease is genuinely hard to enroll, MG Composite and MG-ADL are FDA-validated endpoints, and the durability follow-up addresses the main mechanistic question (does killing plasma cells actually stop pathogenic antibody production long-term). Concerns: n=30 is small, and the treatment effect on the MG Composite primary endpoint was more modest than on the ADL secondary. The Phase 3 (NCT06799247) uses MG-ADL as primary, which is the more responsive scale but also the one that showed the strongest signal in Phase 2b. That is a defensible choice (patient-reported functional outcomes are the modern regulatory standard, and efgartigimod's own approval was built on MG-ADL) but does risk endpoint-shopping optics if the Phase 3 hits ADL without also hitting MG Composite as a key secondary [3].

Our model estimates a 4% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 30%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and smaller-than-typical enrollment for this phase. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk sits mainly in endpoint translation. Phase 2b hit MG-ADL cleanly but the MG Composite primary was more marginal at the earliest timepoint [1]. A Phase 3 in a broader population, including patients with different antibody profiles (some MG patients have anti-MuSK antibodies rather than anti-AChR, and BCMA targeting should work on both since it kills the plasma cells regardless of what antibody they make, but the trial needs to actually show it), could produce a smaller average effect. Safety risk is currently the differentiating strength: no CRS (cytokine release syndrome, the systemic inflammatory response driven by CAR-T activation), no ICANS (immune effector cell-associated neurotoxicity syndrome, the CAR-T-associated brain toxicity), and no lymphodepletion in the reported data [1][6]. That profile has to hold at Phase 3 scale. One severe CRS or ICANS event in a non-cancer patient population is a much bigger deal than in refractory myeloma. Execution risk: autologous cell therapy manufacturing at commercial scale is expensive and slow. Cartesian's mRNA platform is theoretically cheaper than a viral CAR-T (no viral vector, no lentivirus GMP, meaning no Good Manufacturing Practice production of live virus), but still requires apheresis, cell manufacturing, and cold chain. Commercial risk is real. Efgartigimod (Vyvgart, argenx) generated approximately $2.2B in 2024 and is dosed as a subcutaneous injection [9]. Convincing payers and patients to prefer a multi-infusion cell therapy over a self-administered biologic requires a differentiated outcome. Probably deeper responses, longer durability without redosing, or drug-free remission. Anti-AChR titer reduction plus real-world drug-holiday data would be the clearest wedge.

Watch this closely. The signal to check for is the Phase 3 primary readout on MG-ADL at the pre-specified timepoint in NCT06799247, currently enrolling with a target of 100 patients [3]. A confirmed placebo-controlled effect with the safety profile intact would be one of the more consequential autoimmune data points of the late-2020s cycle, because it would validate the whole thesis of using plasma-cell-directed cell therapy for antibody-mediated autoimmune disease. That opens the door to lupus, myositis, and a long list of other indications Cartesian is already pursuing [10][11]. On the addressable population: US gMG prevalence is roughly 65,000 to 80,000. Reasonably, about a third (roughly 20,000 to 30,000) are refractory or inadequately controlled on current standard of care (efgartigimod, rituximab, complement inhibitors like eculizumab and ravulizumab). A realistic Year-5 penetration rate for a first-approved cell therapy in this space is 5 to 15% of that refractory pool, or 1,000 to 4,500 US patients. At a plausible net price in the $400K to $600K range per treatment course, that maps to a several-hundred-million to low-single-digit-billion US peak sales opportunity, plus ex-US and label-expansion optionality. Orphan Drug Designation locks in 7-year post-approval exclusivity, a meaningful moat during that ramp. Cartesian Therapeutics (RNAC) is a small-cap biotech with a fully diluted market cap in the $500M range per the FY2025 10-K [4]. That valuation is dominated by expectations around Descartes-08. A positive Phase 3 realistically doubles or triples the equity value and makes the company a plausible acquisition target for a large pharma looking for a foothold in cell therapy for autoimmune disease (AstraZeneca, BMS, and Novartis all have publicly stated interest in this space). A miss on the primary endpoint likely takes the stock below cash. Next checkpoint: any interim safety or enrollment update, plus a public conference presentation on durability data beyond one year. The next scheduled Cartesian earnings call is the natural venue.